Trials / Active Not Recruiting
Active Not RecruitingNCT04522323
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 101 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
Detailed description
The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI5752 in combination with Lenvatinib (or Axitinib) in subjects with advanced renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI5752 | MEDI5752 |
| DRUG | Axitinib | INLYTA |
| DRUG | Lenvatinib | LENVIMA |
Timeline
- Start date
- 2020-08-05
- Primary completion
- 2025-09-26
- Completion
- 2025-09-26
- First posted
- 2020-08-21
- Last updated
- 2025-07-25
Locations
20 sites across 4 countries: United States, Australia, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04522323. Inclusion in this directory is not an endorsement.